Pulmonary hypertension combination therapy may lead to greater disease burden

Patients with pulmonary arterial hypertension (PAH) receiving combination therapy with intravenous (IV) PGI2 may suffer from greater disease burden compared with those receiving monotherapy or combination therapy, excluding IV PGI2.

Researchers from Massachusetts General Hospital and Novartis Pharma AG in Switzerland performed statistical tests on 446 patients with PAH, of which (a) 337 were receiving monotherapy; (b) 88 were receiving non-IV PGI2 combination therapy; and (c) 21 were receiving IV PGI2 .

Results showed that pulmonary vascular resistance, mean number of PAH-related hospitalizations, and dyspnea scores were highest in those treated with IV PGI2.

This study was presented during CHEST 2012, the annual meeting of the , held October 20 – 25, in Atlanta, Georgia.

add to favorites email to friend print save as pdf

Related Stories

Gene therapy may be effective in treating PAH

May 19, 2010

Gene therapy has been shown to have positive effects in rat models of pulmonary arterial hypertension (PAH), according to researchers at the University of Adelaide in Australia.

Recommended for you

In US, Ebola fears rise but most confident in response

2 hours ago

After two health care workers in Texas were infected with Ebola while caring for a Liberian patient, a poll Tuesday showed a rattled US public that nevertheless stayed confident in the government's response.

'Humbled' NBC cameraman recovers from Ebola

2 hours ago

A US photojournalist said Tuesday he was grateful to be alive after the hospital treating him declared him now free of Ebola, in a minor victory over the virus that has killed more than 4,500 people.

User comments